Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer.

Yim SY, Shim JJ, Shin JH, Jeong YS, Kang SH, Kim SB, Eun YG, Lee DJ, Conner EA, Factor VM, Moore DD, Johnson RL, Thorgeirsson SS, Lee JS.

Mol Cancer Res. 2018 Aug 6. pii: molcanres.0313.2018. doi: 10.1158/1541-7786.MCR-18-0313. [Epub ahead of print]

PMID:
30082483
2.

Hemodynamics and Perfusion in Premature Infants During Transfusion.

Weaver B, Guerreso K, Conner EA, Russell K, Vogel R, Rodriguez M.

AACN Adv Crit Care. 2018 Summer;29(2):126-137. doi: 10.4037/aacnacc2018402.

PMID:
29875109
3.

Structure-function relationships for the selective inhibition of human 3β-hydroxysteroid dehydrogenase type 1 by a novel androgen analog.

Pham JH, Will CM, Mack VL, Halbert M, Conner EA, Bucholtz KM, Thomas JL.

J Steroid Biochem Mol Biol. 2017 Nov;174:257-264. doi: 10.1016/j.jsbmb.2017.10.004. Epub 2017 Oct 12.

PMID:
29031687
4.

Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress.

Gomez-Quiroz LE, Seo D, Lee YH, Kitade M, Gaiser T, Gillen M, Lee SB, Gutierrez-Ruiz MC, Conner EA, Factor VM, Thorgeirsson SS, Marquardt JU.

Toxicology. 2016 Jun 15;361-362:39-48. doi: 10.1016/j.tox.2016.07.004. Epub 2016 Jul 6.

5.

Possible role of anti-SSA/Ro antibodies in the pathogenesis of pulmonary hypertension.

Guerreso K, Conner EA.

Respir Med Case Rep. 2016 Jan 12;17:47-9. doi: 10.1016/j.rmcr.2016.01.001. eCollection 2016.

6.

DNMT1 is a required genomic regulator for murine liver histogenesis and regeneration.

Kaji K, Factor VM, Andersen JB, Durkin ME, Tomokuni A, Marquardt JU, Matter MS, Hoang T, Conner EA, Thorgeirsson SS.

Hepatology. 2016 Aug;64(2):582-98. doi: 10.1002/hep.28563. Epub 2016 Apr 28.

7.

Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype.

Matter MS, Marquardt JU, Andersen JB, Quintavalle C, Korokhov N, Stauffer JK, Kaji K, Decaens T, Quagliata L, Elloumi F, Hoang T, Molinolo A, Conner EA, Weber A, Heikenwalder M, Factor VM, Thorgeirsson SS.

Hepatology. 2016 Jun;63(6):1888-99. doi: 10.1002/hep.28487. Epub 2016 Mar 15.

8.

Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer.

Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, Kitade M, Domínguez MP, Castven D, Breuhahn K, Conner EA, Galle PR, Andersen JB, Factor VM, Thorgeirsson SS.

J Hepatol. 2015 Sep;63(3):661-9. doi: 10.1016/j.jhep.2015.04.018. Epub 2015 May 1.

9.

The transcription factor GTF2IRD1 regulates the topology and function of photoreceptors by modulating photoreceptor gene expression across the retina.

Masuda T, Zhang X, Berlinicke C, Wan J, Yerrabelli A, Conner EA, Kjellstrom S, Bush R, Thorgeirsson SS, Swaroop A, Chen S, Zack DJ.

J Neurosci. 2014 Nov 12;34(46):15356-68. doi: 10.1523/JNEUROSCI.2089-14.2014.

10.

MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism.

Akita H, Marquardt JU, Durkin ME, Kitade M, Seo D, Conner EA, Andersen JB, Factor VM, Thorgeirsson SS.

Cancer Res. 2014 Oct 15;74(20):5903-13. doi: 10.1158/0008-5472.CAN-14-0527. Epub 2014 Sep 4.

11.

Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2.

Lee YH, Seo D, Choi KJ, Andersen JB, Won MA, Kitade M, Gómez-Quiroz LE, Judge AD, Marquardt JU, Raggi C, Conner EA, MacLachlan I, Factor VM, Thorgeirsson SS.

Cancer Res. 2014 Sep 1;74(17):4752-61. doi: 10.1158/0008-5472.CAN-13-3531. Epub 2014 Jun 23.

12.

Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits.

Marquardt JU, Seo D, Andersen JB, Gillen MC, Kim MS, Conner EA, Galle PR, Factor VM, Park YN, Thorgeirsson SS.

J Hepatol. 2014 Feb;60(2):346-353. doi: 10.1016/j.jhep.2013.10.014. Epub 2013 Oct 26.

13.

Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling.

Kitade M, Factor VM, Andersen JB, Tomokuni A, Kaji K, Akita H, Holczbauer A, Seo D, Marquardt JU, Conner EA, Lee SB, Lee YH, Thorgeirsson SS.

Genes Dev. 2013 Aug 1;27(15):1706-17. doi: 10.1101/gad.214601.113.

14.

mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA, Tanaka K, Matsutani T, Iwanami A, Aronow BJ, Manway L, Maira SM, Thorgeirsson SS, Mischel PS, Thomas G, Kozma SC.

Sci Transl Med. 2012 Jun 20;4(139):139ra84. doi: 10.1126/scitranslmed.3003923. Epub 2012 Apr 25.

15.

Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways.

Marquardt JU, Seo D, Gómez-Quiroz LE, Uchida K, Gillen MC, Kitade M, Kaposi-Novak P, Conner EA, Factor VM, Thorgeirsson SS.

Biochim Biophys Acta. 2012 Jun;1822(6):942-51. doi: 10.1016/j.bbadis.2012.02.012. Epub 2012 Feb 22.

16.

Contribution of hepatic lineage stage-specific donor memory to the differential potential of induced mouse pluripotent stem cells.

Lee SB, Seo D, Choi D, Park KY, Holczbauer A, Marquardt JU, Conner EA, Factor VM, Thorgeirsson SS.

Stem Cells. 2012 May;30(5):997-1007. doi: 10.1002/stem.1074.

17.

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.

Gastroenterology. 2012 Apr;142(4):1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005. Epub 2011 Dec 13.

18.

Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice.

Ishikawa T, Factor VM, Marquardt JU, Raggi C, Seo D, Kitade M, Conner EA, Thorgeirsson SS.

Hepatology. 2012 Apr;55(4):1215-26. doi: 10.1002/hep.24796.

19.

Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer.

Coulouarn C, Factor VM, Conner EA, Thorgeirsson SS.

Carcinogenesis. 2011 Oct;32(10):1434-40. doi: 10.1093/carcin/bgr133. Epub 2011 Jul 18.

20.

Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways.

Marquardt JU, Raggi C, Andersen JB, Seo D, Avital I, Geller D, Lee YH, Kitade M, Holczbauer A, Gillen MC, Conner EA, Factor VM, Thorgeirsson SS.

Hepatology. 2011 Sep 2;54(3):1031-42. doi: 10.1002/hep.24454. Epub 2011 Jul 27.

21.

Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.

Lee YH, Judge AD, Seo D, Kitade M, Gómez-Quiroz LE, Ishikawa T, Andersen JB, Kim BK, Marquardt JU, Raggi C, Avital I, Conner EA, MacLachlan I, Factor VM, Thorgeirsson SS.

Oncogene. 2011 Oct 6;30(40):4175-84. doi: 10.1038/onc.2011.126. Epub 2011 Apr 18.

22.

Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer.

Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, Thorgeirsson SS.

J Hepatol. 2011 Feb;54(2):311-9. doi: 10.1016/j.jhep.2010.06.036. Epub 2010 Sep 7.

23.

An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer.

Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS.

Sci Transl Med. 2010 Oct 20;2(54):54ra77. doi: 10.1126/scitranslmed.3001338.

24.

Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma.

Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, Marquardt JU, Kitade M, Durkin ME, Raggi C, Woo HG, Conner EA, Avital I, Maclachlan I, Factor VM, Thorgeirsson SS.

Cancer Res. 2010 Nov 1;70(21):8264-9. doi: 10.1158/0008-5472.CAN-10-0749. Epub 2010 Oct 19.

25.

Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice.

Factor VM, Seo D, Ishikawa T, Kaposi-Novak P, Marquardt JU, Andersen JB, Conner EA, Thorgeirsson SS.

PLoS One. 2010 Sep 16;5(9). pii: e12739. doi: 10.1371/journal.pone.0012739.

26.

Central role of c-Myc during malignant conversion in human hepatocarcinogenesis.

Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, Conner EA, Factor VM, Roskams T, Thorgeirsson SS.

Cancer Res. 2009 Apr 1;69(7):2775-82. doi: 10.1158/0008-5472.CAN-08-3357. Epub 2009 Mar 10. Erratum in: Cancer Res. 2009 Apr 15;69(8):3721. Coulouarn, Cedric [added].

27.

E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.

Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS.

Gastroenterology. 2008 Oct;135(4):1322-32. doi: 10.1053/j.gastro.2008.07.012. Epub 2008 Jul 17.

28.

Proteomic and metabolomic biomarkers for III-V semiconductors: and prospects for application to nano-materials.

Fowler BA, Conner EA, Yamauchi H.

Toxicol Appl Pharmacol. 2008 Nov 15;233(1):110-5. doi: 10.1016/j.taap.2008.01.014. Epub 2008 Jan 31.

PMID:
18353413
29.

Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis.

Gómez-Quiroz LE, Factor VM, Kaposi-Novak P, Coulouarn C, Conner EA, Thorgeirsson SS.

J Biol Chem. 2008 May 23;283(21):14581-9. doi: 10.1074/jbc.M707733200. Epub 2008 Mar 18.

30.

Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis.

Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS.

Cancer Res. 2007 Oct 15;67(20):9844-51.

31.

Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS.

J Clin Invest. 2007 Sep;117(9):2713-22.

32.

Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis.

Coulouarn C, Gomez-Quiroz LE, Lee JS, Kaposi-Novak P, Conner EA, Goldina TA, Onishchenko GE, Factor VM, Thorgeirsson SS.

Hepatology. 2006 Oct;44(4):1003-11.

PMID:
17006931
33.

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS.

Gastroenterology. 2006 Apr;130(4):1117-28.

PMID:
16618406
34.

Metabolomic and proteomic biomarkers for III-V semiconductors: chemical-specific porphyrinurias and proteinurias.

Fowler BA, Conner EA, Yamauchi H.

Toxicol Appl Pharmacol. 2005 Aug 7;206(2):121-30.

PMID:
15967200
35.

Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-Myc/E2F1 transgenic mouse model of liver cancer.

Calvisi DF, Conner EA, Ladu S, Lemmer ER, Factor VM, Thorgeirsson SS.

J Hepatol. 2005 Jun;42(6):842-9. Epub 2005 Apr 8.

PMID:
15885355
36.

Intact signaling by transforming growth factor beta is not required for termination of liver regeneration in mice.

Oe S, Lemmer ER, Conner EA, Factor VM, Levéen P, Larsson J, Karlsson S, Thorgeirsson SS.

Hepatology. 2004 Nov;40(5):1098-105.

PMID:
15389868
37.

Disregulation of E-cadherin in transgenic mouse models of liver cancer.

Calvisi DF, Ladu S, Conner EA, Factor VM, Thorgeirsson SS.

Lab Invest. 2004 Sep;84(9):1137-47.

38.

Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice.

Calvisi DF, Factor VM, Ladu S, Conner EA, Thorgeirsson SS.

Gastroenterology. 2004 May;126(5):1374-86.

PMID:
15131798
39.

Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair.

Huh CG, Factor VM, Sánchez A, Uchida K, Conner EA, Thorgeirsson SS.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4477-82.

40.

Dysregulation of DNA repair pathways in a transforming growth factor alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis.

Hironaka K, Factor VM, Calvisi DF, Conner EA, Thorgeirsson SS.

Lab Invest. 2003 May;83(5):643-54.

PMID:
12746474
41.

E2F1 blocks and c-Myc accelerates hepatic ploidy in transgenic mouse models.

Conner EA, Lemmer ER, Sánchez A, Factor VM, Thorgeirsson SS.

Biochem Biophys Res Commun. 2003 Feb 28;302(1):114-20.

PMID:
12593856
42.

Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.

Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS.

Oncogene. 2000 Oct 19;19(44):5054-62.

43.

HGF-mediated apoptosis via p53/bax-independent pathway activating JNK1.

Conner EA, Teramoto T, Wirth PJ, Kiss A, Garfield S, Thorgeirsson SS.

Carcinogenesis. 1999 Apr;20(4):583-90.

PMID:
10223185
44.

Growth inhibition and induction of apoptosis by HGF in transformed rat liver epithelial cells.

Conner EA, Wirth PJ, Kiss A, Santoni-Rugiu E, Thorgeirsson SS.

Biochem Biophys Res Commun. 1997 Jul 18;236(2):396-401.

PMID:
9240448
45.

Aberrant expression and regulation of hepatic epidermal growth factor receptor in a c-myc transgenic mouse model.

Woitach JT, Conner EA, Wirth PJ, Thorgeirsson SS.

J Cell Biochem. 1997 Mar 15;64(4):651-60.

PMID:
9093914
46.

Protein alterations associated with gene amplification in cultured human and rodent cells.

Conner EA, Wirth PJ.

Electrophoresis. 1996 Jul;17(7):1257-64.

PMID:
8855414
47.

Protocol for releasing Novacor left ventricular assist system patients out-of-hospital.

Pristas JM, Winowich S, Nastala CJ, Gifford J, Conner EA, Borovetz HS, Griffith BP, Portner PM, Kormos RL.

ASAIO J. 1995 Jul-Sep;41(3):M539-43.

PMID:
8573863
48.

Alterations in the heme biosynthetic pathway from the III-V semiconductor metal, indium arsenide (InAs).

Conner EA, Yamauchi H, Fowler BA.

Chem Biol Interact. 1995 Jun 14;96(3):273-85.

PMID:
7538452
49.

Implications of lead binding proteins for risk assessment of lead exposure.

Fowler BA, Kahng MW, Smith DR, Conner EA, Laughlin NK.

J Expo Anal Environ Epidemiol. 1993 Oct-Dec;3(4):441-8.

PMID:
8173344
50.

Biological indicators for monitoring exposure/toxicity from III-V semiconductors.

Conner EA, Yamauchi H, Fowler BA, Akkerman M.

J Expo Anal Environ Epidemiol. 1993 Oct-Dec;3(4):431-40.

PMID:
8173343

Supplemental Content

Loading ...
Support Center